101909-43-7 Usage
General Description
Methyl 4-bromo-1H-indole-3-carboxylate is a chemical compound often used in research and scientific studies, especially within the pharmaceutical industry. It belongs to the class of organic compounds known as indoles, characterized by a structure that contains a benzene ring fused to a pyrrole ring. Its systematic name is methyl 4-bromo-1H-indole-3-carboxylate and its molecular formula is C10H8BrNO2. It is typically presented as a beige crystalline powder. While it plays a critical role in the development of certain pharmaceuticals, it needs to be handled with care due to its potential for causing skin and eye irritation.
Check Digit Verification of cas no
The CAS Registry Mumber 101909-43-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,1,9,0 and 9 respectively; the second part has 2 digits, 4 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 101909-43:
(8*1)+(7*0)+(6*1)+(5*9)+(4*0)+(3*9)+(2*4)+(1*3)=97
97 % 10 = 7
So 101909-43-7 is a valid CAS Registry Number.
InChI:InChI=1/C10H8BrNO2/c1-14-10(13)6-5-12-8-4-2-3-7(11)9(6)8/h2-5,12H,1H3
101909-43-7Relevant articles and documents
A New Synthesis of Lysergic Acid
Hendrickson, James B.,Wang, Jian
, p. 3 - 5 (2004)
(Equation presented) (±)-Lysergic acid (1) has been synthesized via an economical 8-step route from 4-bromoindole and isocinchomeronic acid without the need to protect the indole during the synthesis. Initial efforts to form the simpler 3-acylindole derivatives first and then cyclize these were unsuccessful in the cyclization step.
PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF
-
Paragraph 00582-00583, (2020/12/30)
Disclosed herein are compounds, compositions, and methods for modulating the prostaglandin E2 receptor 4 (EP4) with the compounds and compositions disclosed herein. Also described are methods of treating diseases or disorders that are mediated by the acti
INDOLE COMPOUND AND USE THEREOF
-
, (2008/06/13)
The present invention relates to a compound represented by the formula (I), wherein all symbols are as defined in the description, a salt thereof a solvate thereof, or a prodrug thereof, which has a leukotriene receptor antagonistic activity which is expe